

The background is a light gray gradient. In the top-left and bottom-right corners, there are several realistic water droplets of various sizes, some overlapping. The word "DIURETICS" is centered in a bold, red, serif font.

DIURETICS

REFERENCES

- **BRODY'S HUMAN PHARMACOLOGY, 4TH EDITION**

- **GUYTON HUMAN PHYSIOLOGY**

OUTLINE

1. SITES OF DRUG ACTION

2. OSMOTIC DIURETICS

3. CARBONIC ANHYDRASE INHIBITORS

4. THIAZIDE DIURETICS

5. LOOP DIURETICS

6. POTASSIUM-SPARING DIURETICS

DEFINITIONS

Diuretic: substance that promotes the excretion of urine

- caffeine, yerba mate, nettles, cranberry juice, alcohol

• **Natriuretic:** substance that promotes the renal excretion of Na^+



RENAL PHYSIOLOGY

renal epithelial transport

tubular reabsorption

proximal tubule

loop of Henle


thick ascending limb


distal convoluted tubule

collecting tubule


tubular secretion

collecting tubules





SUMMARY: SITES OF ACTION



OSMOTIC DIURETICS

do not interact with receptors or directly block renal transport



• **activity dependent on development of osmotic pressure**

• **Mannitol (prototype)**

• **Urea**

• **Glycerol**

• **Isosorbide**




MECHANISM OF ACTION


osmotic diuretics are not reabsorbed

- **increases osmotic pressure specifically in the proximal tubule and loop of Henle**
- **prevents passive reabsorption of H₂O**
- **osmotic force solute in lumen > osmotic force of reabsorbed Na⁺**
- **increased H₂O and Na⁺ excretion**

↑glucose filtration



Osmotic diuresis



THERAPEUTIC USES

Mannitol

- **drug of choice: non-toxic, freely filtered, non-reabsorbable and non-metabolized**
- **administered prophylactically for acute renal failure secondary to trauma, CVS disease, surgery or nephrotoxic drugs**
- **short-term treatment of acute glaucoma**
- **infused to lower intracranial pressure**
- **Urea, glycerol and isosorbide are less efficient**
- **can penetrate cell membranes**

SIDE EFFECTS

increased extracellular fluid volume

- **cardiac failure**

- **pulmonary edema**


- **hypernatremia**

- **hyperkalemia secondary to diabetes or impaired renal function**

- **headache, nausea, vomiting**


CARBONIC ANHYDRASE INHIBITORS

- **limited uses as diuretics**
- **Acetazolamide**
 - **prototype carbonic anhydrase inhibitor**
 - **developed from sulfanilamide (caused metabolic acidosis and alkaline urine)**



MECHANISM OF ACTION

- inhibits carbonic anhydrase in renal proximal tubule cells
- carbonic anhydrase catalyzes formation of HCO_3^- and H^+ from H_2O and CO_2
- inhibition of carbonic anhydrase decreases $[\text{H}^+]$ in tubule lumen
- less H^+ for Na^+/H^+ exchange
- increased lumen Na^+ , increased H_2O retention



THERAPEUTIC USES

used to treat chronic open-angle glaucoma

- **aqueous humor has high HCO_3^-**
- **acute mountain sickness**
- **prevention and treatment**
- **metabolic alkalosis**
- **sometimes epilepsy**
- **mostly used in combination with other diuretics in resistant patients**

SIDE EFFECTS

- rapid tolerance**
- increased HCO_3^- excretion causes metabolic acidosis**
- drowsiness**
- fatigue**
- CNS depression**
- paresthesia (pins and needles under skin)**
- nephrolithiasis (renal stones)**
- K^+ wasting**

THIAZIDE DIURETICS


active in distal convoluted tubule

• **Chlorothiazide (prototype)**

• **Hydrochlorothiazide**

• **Chlorthalidone**

• **Metolazone**



MECHANISM OF ACTION


- **inhibit Na^+ and Cl^- transporter in distal convoluted tubules**

- **increased Na^+ and Cl^- excretion**

- **weak inhibitors of carbonic anhydrase, increased HCO_3^- excretion**

- **increased $\text{K}^+/\text{Mg}^{2+}$ excretion**

- **decrease Ca^{2+} excretion**



THERAPEUTIC USES

hypertension

• **congestive heart failure**

• **hypercalciuria: prevent excess Ca^{2+} excretion to form stones in ducts**

• **osteoporosis**

• **nephrogenic diabetes insipidus**

• **treatment of Li^{+} toxicity**

PHARMACOKINETICS

orally administered

• **poor absorption**

• **onset of action in ~ 1 hour**

• **wide range of $T_{1/2}$ amongst different thiazides, longer than loop diuretics**

• **free drug enters tubules by filtration and by organic acid secretion**

SIDE EFFECTS

hypokalemia

increased Na⁺ exchange in CCD

• **volume-contraction induced aldosterone release**

• **hyponatremia**

• **hyperglycemia**

• **diminished insulin secretion**

• **elevated plasma lipids**

• **hyperuricemia**

• **hypercalcemia**

LOOP DIURETICS


active in “loop” of Henle

- **Furosemide (prototype)**


- **Bumetanide**

- **Torsemide**


- **Ethacrynic acid**



Furosemide



Bumetanide



Ethacrynic acid

MECHANISM OF ACTION

enter proximal tubule via organic acid transporter


inhibits apical Na-K-2Cl transporter in thick ascending loop of henle

competes with Cl⁻ binding site

enhances passive Mg²⁺ and Ca²⁺ excretion

increased K⁺ and H⁺ excretion in CCD

inhibits reabsorption of ~25% of glomerular filtrate



THERAPEUTIC USES

- **edema: cardiac, pulmonary or renal**
- **chronic renal failure or nephrosis**
- **hypertension**
- **hypercalcemia**
- **acute and chronic hyperkalemia**

PHARMACOKINETICS

orally administered, rapid absorption

rapid onset of action

- **bound to plasma proteins: displaced by warfarin, and clofibrate**
- **increase toxicity of cephalosporin antibiotics and lithium**
- **additive toxicity with other ototoxic drugs**
- **inhibitors of organic acid ion transport decrease potency (i.e. probenecid, NSAID's)**

SIDE EFFECTS

- **hypokalemia**
- **hyperuricemia**
- **metabolic alkalosis**
- **hyponatremia**
- **ototoxicity**
- **Mg²⁺ depletion**

K⁺ SPARING DIURETICS

three groups

• **steroid aldosterone antagonists**




• **spironolactone, eplerenone**

• **Pteridines**

• **triamterene**

• **Pyrazinoylguanidines**

• **amiloride**



Amiloride

MECHANISM OF ACTION

K⁺ sparing diuretics function in CCD

decrease Na⁺ transport in collecting tubule

Spironolactone

competitive antagonist for mineralocorticoid receptor


prevents aldosterone stimulated increases in Na⁺ transporter expression

Triamterene/Amiloride

organic bases

secreted into lumen by proximal tubule cells

inhibit apical Na⁺ channel



THERAPEUTIC USES

- **primary hyperaldosteronism (adrenal adenoma, bilateral adrenal hyperplasia)**
- **congestive heart failure**
- **cirrhosis**
- **nephrotic syndrome**
- **in conjunction with K^+ wasting diuretics**

PHARMACOKINETICS

Spironolactone

- orally administered

- aldactazide: spironolactone/thiazide combo

Amiloride

- oral administration, 50% effective

- not metabolized

- not bound to plasma proteins

Triamterine

- oral administration, 50% effective

- 60% bound to plasma proteins

- liver metabolism, active metabolites

SIDE EFFECTS

- **hyperkalemia: monitor plasma [K⁺]**
- **spironolactone: gynecomastia**
- **triamterene: megaloblastic anemia in cirrhosis patients**
- **amiloride: increase in blood urea nitrogen, glucose intolerance in diabetes mellitus**